SHARE

Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) reported that its HbA1c testing solution, known as the ‘cobas c 513 analyser’, is now available for nations approving the CE mark.1. Roland Diggelmann, the COO of Roche Diagnostics, said that the increasing number of diabetic patients is challenging healthcare provider firms and is posing considerable pressure on healthcare systems. With the new product cobas c 513, the company is meeting the growing testing needs of clients.

The new launch

With the cobas c 513, Roche Holding is replacing its existing HbA1c analyser, known as the ‘COBAS INTEGRA 800 CTS’, which has proven a successful solution. The new product further enhances lab efficiency by doubling the supply of the INTEGRA 800 CTS to 400 patients from 200 patient results per hour. Roche reported that the cobas c 513 delivers similar strong performance. It boasts direct results reporting, thus reducing the peril of result misinterpretation and removing the need to conduct lengthy manual result interpretation.

This not only saves valuable time and lab resources but also ensures high quality of results. Additionally, the new analyser offers a higher on-board assessment capacity. Enabling labs to load the c 513 analyser with additional tests at same time releases lab resources, saves lab space and ensures a uninterrupted workflow. The cobas c 513 analyser features closed tube sampling, which prevents sample contamination, minimizes hands-on time, and promotes operator safety for lab staff.

The scope

The number of diabetic patients has increased considerably in recent years, with projection of 566 million people with diabetes globally. This number is expected to jump by 53% by 2035, putting a remarkable pressure on healthcare provider firms. It should be noted that more than 50% diabetes cases are preventable. Roche’s new analyser is based on the trusted and proven cobas technology formulated in cooperation with HHT.

In last trading session, the stock price of Roche Holding gained 0.36% to close the day at $33.44.

rhh

Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) managed to maintain its short term uptrend for another session and finished the last trading session with a minor gain of 0.36%. The volume of the day at 1 million was slightly lower than the daily average of 1.4 million, reflecting the lack of enthusiasm on the part of the buyers. The stock is now very close to the short term swing high and a strong supply area around $34 and the probability of a correction looks higher at this point of time. The short term structure of the stock doesn’t look very strong to break above $34 at the very first attempt.

LEAVE A REPLY